BioAtla (BCAB) Competitors $0.38 -0.01 (-2.40%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.37 -0.02 (-3.98%) As of 05/21/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. IZTC, XBIT, ENTX, IVVD, CHRS, CRDL, IMUX, ZNTL, KYTX, and ORMPShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Invizyne Technologies (IZTC), XBiotech (XBIT), Entera Bio (ENTX), Invivyd (IVVD), Coherus BioSciences (CHRS), Cardiol Therapeutics (CRDL), Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Kyverna Therapeutics (KYTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Invizyne Technologies XBiotech Entera Bio Invivyd Coherus BioSciences Cardiol Therapeutics Immunic Zentalis Pharmaceuticals Kyverna Therapeutics Oramed Pharmaceuticals Invizyne Technologies (NASDAQ:IZTC) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Do analysts prefer IZTC or BCAB? BioAtla has a consensus target price of $5.00, suggesting a potential upside of 1,208.22%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders hold more shares of IZTC or BCAB? 77.2% of BioAtla shares are owned by institutional investors. 11.5% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, IZTC or BCAB? Invizyne Technologies has higher earnings, but lower revenue than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/ABioAtla$11M2.03-$123.46M-$1.22-0.31 Does the MarketBeat Community prefer IZTC or BCAB? BioAtla received 25 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformInvizyne TechnologiesN/AN/ABioAtlaOutperform Votes2565.79% Underperform Votes1334.21% Is IZTC or BCAB more profitable? Invizyne Technologies' return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A BioAtla N/A -187.30%-96.33% Does the media prefer IZTC or BCAB? In the previous week, BioAtla had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.00 beat BioAtla's score of -0.50 indicating that Invizyne Technologies is being referred to more favorably in the media. Company Overall Sentiment Invizyne Technologies Neutral BioAtla Negative SummaryBioAtla beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.33M$2.93B$5.38B$8.39BDividend YieldN/A1.71%5.21%4.10%P/E Ratio-0.2230.5026.8019.71Price / Sales2.03400.15389.55117.28Price / CashN/A168.6838.2534.62Price / Book0.263.286.804.50Net Income-$123.46M-$72.17M$3.23B$248.18M7 Day Performance-10.85%2.96%1.53%0.23%1 Month Performance10.46%3.25%10.05%12.39%1 Year Performance-83.24%-28.29%16.75%7.07% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.012 of 5 stars$0.38-2.4%$5.00+1,208.2%-83.6%$22.33M$11M-0.2260Gap UpIZTCInvizyne TechnologiesN/A$15.04+11.0%N/AN/A$94.03MN/A0.00N/AXBITXBiotech0.4977 of 5 stars$3.07+1.0%N/A-67.2%$93.60M$4.01M-2.84100Positive NewsGap UpENTXEntera Bio1.8093 of 5 stars$2.05+1.0%$10.00+387.8%-20.1%$93.18M$223,000.00-7.8820News CoverageIVVDInvivyd2.9191 of 5 stars$0.78-0.1%$7.52+869.1%-65.4%$93.04M$25.38M-0.40100Earnings ReportGap DownCHRSCoherus BioSciences3.6933 of 5 stars$0.80+5.1%$4.68+485.4%-62.8%$92.75M$272.25M-10.00330Analyst DowngradeCRDLCardiol Therapeutics1.6152 of 5 stars$1.12+0.9%$8.40+650.0%-52.3%$92.52MN/A-2.8720Positive NewsGap UpIMUXImmunic2.4144 of 5 stars$0.960.0%$13.20+1,274.0%-27.6%$92.05MN/A-0.7870Earnings ReportGap DownZNTLZentalis Pharmaceuticals2.0894 of 5 stars$1.25-0.8%$8.24+559.6%-89.6%$90.66M$26.87M-0.50160Analyst RevisionKYTXKyverna Therapeutics2.3629 of 5 stars$2.07-10.8%$18.33+785.7%-83.9%$89.46M$7.03M-0.6196News CoverageAnalyst RevisionGap DownORMPOramed Pharmaceuticals1.7581 of 5 stars$2.14-0.5%N/A-8.7%$87.42M$1.34M19.4510Earnings Report Related Companies and Tools Related Companies IZTC Alternatives XBIT Alternatives ENTX Alternatives IVVD Alternatives CHRS Alternatives CRDL Alternatives IMUX Alternatives ZNTL Alternatives KYTX Alternatives ORMP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
